Home > Insider Trading > Filing (0001209191-21-058122)

Filing Details

Accession Number:: 0001209191-21-058122
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-29 19:15:51
Reporting Period:: 2021-09-27

Accepted Time:: 2021-09-29 19:15:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1733294	Generation Bio Co.	GBIO	Pharmaceutical Preparations (2834)	814301281

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1742765	Atlas Venture Associates X, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1742766	Atlas Venture Associates X, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1759241	Atlas Venture Opportunity Fund I, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780066	Atlas Venture Associates Opportunity I, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-27	51,294	$25.70	29,645	No	4	S	Direct
Common Stock	Disposition	2021-09-27	95	$25.70	662	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-28	13,089	$25.24	16,556	No	4	S	Direct
Common Stock	Disposition	2021-09-28	24	$25.24	638	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-09-29	16,556	$24.59	0	No	4	S	Direct
Common Stock	Disposition	2021-09-29	30	$24.59	608	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See footnote
No	4	S	Direct
No	4	S	Indirect	See footnote
No	4	S	Direct
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,111,939	Indirect	See footnote
Common Stock	1,166,937	Indirect	See footnote

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan dated April 20, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.15 to $26.07 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6).
The shares are held directly by Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.
The shares are held directly by Atlas Venture Associates Opportunity I, LP ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVAO LP except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.93 to $25.79 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.46 to $25.36 inclusive.
The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is AVA X LP. AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.